NHS drugs prices set to rise as Starmer to cave on Trump demands
NHS drug prices seem to rise because Sir Keir Starmer will be close to donald Trump’s requests for paying more money to pharmaceutical companies.
Authorities, Trump administration, NHS’nin at the beginning of this week to adjust the drugs of drugs to adjust the new offers, while the National Institute of Health and Care Excellence (NICE) increases the threshold of 25 percent.
First reported revelation PolicyIs it an attempt to avoid the new wave of new tariffs that are threatened to what the government Trump believes that British believes are contrary to competition?
In accordance with the existing rules, the beautiful threshold measures whether a treatment offers a good value for money. This is considered a good value for each extra quality life it delivers to a patient if a drug costs NHS.
However, under new offers to the White House, this threshold would be raised, that is, England will generally pay more for drugs.
While resisting any changes, the Treasury told a source that they will not provide any extra benefit. Policy: “This is the price you need to pay after Trump to keep Global Pharma play in England.”
After making a trade agreement with the country, the Prime Minister comes while trying to make positive headlines on trade on a trip to India.
However, the price increase is a sour note that Trump is a positive relationship with the White House, which Sir Keir managed to secure the first trade agreement to open the comprehensive tariff regime initiated earlier this year.
In addition, there is a headache in the hope that the UK’s steel tariffs will reduce their steel tariffs from 25 percent to zero, and they apparently talks months after the Hoping Street will make an agreement.
Trump threatened to apply up to 100 percent high tariffs for pharmaceutical imports. This provides “preferential treatment üzerinde on tariffs based on improved pricing for American pharmaceutical companies operating in the UK.
The UK Government Spokesman: “The pharmaceutical sector and its innovative drugs are critical for our NHS, economy and change plan. With our Plan of Life Sciences Sector Plan, we have undertaken to work with the industry to accelerate the growth in innovative drugs compared to the previous decade.”
The spokesman added: “We have provided an economic partnership that includes working on the export of drugs from the United States and the UK, where we improve the conditions for pharmaceutical companies.
